These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 32519831)

  • 1. Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
    Saad A; de Lima M; Anand S; Bhatt VR; Bookout R; Chen G; Couriel D; Di Stasi A; El-Jawahri A; Giralt S; Gutman J; Ho V; Horwitz M; Hsu J; Juckett M; Kharfan-Dabaja MA; Loren A; Meade J; Mielcarek M; Moreira J; Nakamura R; Nieto Y; Roddy J; Satyanarayana G; Schroeder M; Tan CR; Tzachanis D; Burn J; Pluchino L
    J Natl Compr Canc Netw; 2020 May; 18(5):599-634. PubMed ID: 32519831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022.
    Saad A; Loren A; Bolaños-Meade J; Chen G; Couriel D; Di Stasi A; El-Jawahri A; Elmariah H; Farag S; Gundabolu K; Gutman J; Ho V; Hoeg R; Horwitz M; Hsu J; Kassim A; Kharfan Dabaja M; Magenau J; Martin T; Mielcarek M; Moreira J; Nakamura R; Nieto Y; Ninos C; Oliai C; Patel S; Randolph B; Schroeder M; Tzachanis D; Varshavsky-Yanovsky AN; Vusirikala M; Algieri F; Pluchino LA
    J Natl Compr Canc Netw; 2023 Feb; 21(2):108-115. PubMed ID: 36791762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission.
    Konuma T; Kanda J; Yamasaki S; Harada K; Shimomura Y; Terakura S; Mizuno S; Uchida N; Tanaka M; Doki N; Ozawa Y; Nakamae H; Sawa M; Matsuoka KI; Morishige S; Maruyama Y; Ikegame K; Kimura T; Kanda Y; Ichinohe T; Atsuta Y; Yanada M
    Transplant Cell Ther; 2021 Apr; 27(4):334.e1-334.e11. PubMed ID: 33836881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell-free DNA profiling informs all major complications of hematopoietic cell transplantation.
    Cheng AP; Cheng MP; Loy CJ; Lenz JS; Chen K; Smalling S; Burnham P; Timblin KM; Orejas JL; Silverman E; Polak P; Marty FM; Ritz J; De Vlaminck I
    Proc Natl Acad Sci U S A; 2022 Jan; 119(4):. PubMed ID: 35058359
    [No Abstract]   [Full Text] [Related]  

  • 8. Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial.
    Reshef R; Ganetsky A; Acosta EP; Blauser R; Crisalli L; McGraw J; Frey NV; Hexner EO; Hoxie JA; Loren AW; Luger SM; Mangan J; Stadtmauer EA; Mick R; Vonderheide RH; Porter DL
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):515-521. PubMed ID: 30315941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation.
    El-Jawahri A; Chen YB; Brazauskas R; He N; Lee SJ; Knight JM; Majhail N; Buchbinder D; Schears RM; Wirk BM; Wood WA; Ahmed I; Aljurf M; Szer J; Beattie SM; Battiwalla M; Dandoy C; Diaz MA; D'Souza A; Freytes CO; Gajewski J; Gergis U; Hashmi SK; Jakubowski A; Kamble RT; Kindwall-Keller T; Lazarus HM; Malone AK; Marks DI; Meehan K; Savani BN; Olsson RF; Rizzieri D; Steinberg A; Speckhart D; Szwajcer D; Schoemans H; Seo S; Ustun C; Atsuta Y; Dalal J; Sales-Bonfim C; Khera N; Hahn T; Saber W
    Cancer; 2017 May; 123(10):1828-1838. PubMed ID: 28102896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting.
    Guru Murthy GS; Hari PN; Szabo A; Pasquini M; Narra R; Khan M; Abedin S; Chhabra S; Dhakal B; D'Souza A; Drobyski WR; Rizzo JD; Runaas L; Shah NN; Shaw B; Saber W; Fenske T; Hamadani M
    Biol Blood Marrow Transplant; 2019 Apr; 25(4):827-833. PubMed ID: 30572109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic hematopoietic cell transplantation as consolidation immunotherapy of cancer after autologous transplantation.
    Maris MB; Storb R
    Acta Haematol; 2005; 114(4):221-9. PubMed ID: 16269862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation.
    Majhail NS; Rizzo JD; Lee SJ; Aljurf M; Atsuta Y; Bonfim C; Burns LJ; Chaudhri N; Davies S; Okamoto S; Seber A; Socie G; Szer J; Van Lint MT; Wingard JR; Tichelli A; ; ; ; ; ; ;
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):348-71. PubMed ID: 22178693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.
    Solh M; Zhang X; Connor K; Brown S; Morris LE; Holland HK; Bashey A; Solomon SR
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2192-2198. PubMed ID: 28864140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuation and Nonadherence to Medications for Chronic Conditions after Hematopoietic Cell Transplantation: A 6-Year Propensity Score-Matched Cohort Study.
    Zhou J; Han J; Nutescu EA; Patel PR; Sweiss K; Calip GS
    Pharmacotherapy; 2019 Jan; 39(1):55-66. PubMed ID: 30485471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
    Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
    Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematopoietic Stem Cell Transplant Recipients Surviving at Least 2 Years from Transplant Have Survival Rates Approaching Population Levels in the Modern Era of Transplantation.
    Kliman D; Nivison-Smith I; Gottlieb D; Hamad N; Kerridge I; Purtill D; Szer J; Ma D
    Biol Blood Marrow Transplant; 2020 Sep; 26(9):1711-1718. PubMed ID: 32194285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.
    Kołodziejczak M; Gil L; de la Camara R; Styczyński J;
    Ann Hematol; 2021 Mar; 100(3):763-777. PubMed ID: 33491135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of donor and recipient characteristics on graft-versus-host disease and survival in HLA-matched sibling hematopoietic stem cell transplantation.
    Zhang H
    Transfus Apher Sci; 2020 Jun; 59(3):102743. PubMed ID: 32139282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.